As part of our series focussing on available medicines in Australia, we have added a product review of use of pembrolizumab plus lenvatinib as first-line treatment in patients with advanced renal cell carcinoma.
This review discusses treatment of advanced renal cell carcinoma, indications and dosage, contraindications and a series of clinical studies featuring pembrolizumab plus lenvatinib use. It also provides commentary from Professor Howard Gurney, Director of Clinical Trials and Head of Medical Oncology for the Faculty of Medicine and Health Sciences at Macquarie University.
Please login below to download this issue (PDF)